{"id":"NCT01316887","sponsor":"GlaxoSmithKline","briefTitle":"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A 52 Week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg Once-daily Alone and in Combination With GW642444 25mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01-01","primaryCompletion":"2012-07-01","completion":"2012-07-21","firstPosted":"2011-03-16","resultsPosted":"2014-03-20","lastUpdate":"2018-05-02"},"enrollment":563,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"OTHER"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"125/25 mcg once-daily GSK573719/GW642444","otherNames":[]},{"type":"DRUG","name":"125mcg once-daily GSK573719","otherNames":[]},{"type":"DRUG","name":"Placebo once-daily","otherNames":[]}],"arms":[{"label":"GSK573719/GW642444","type":"EXPERIMENTAL"},{"label":"GSK573719","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication and lung function) of GSK573719/GW642444 Inhalation Powder 125/25mcg in subjects with COPD. The long-term safety of GSK573719 Inhalation Powder 125mcg will also be evaluated. A placebo arm is included to evaluate these products compared to an inactive control.","primaryOutcome":{"measure":"Number of Participants With Any On-treatment Adverse Event (AE) or Any Serious Adverse Event (SAE)","timeFrame":"From the start of study drug up to 52 weeks","effectByArm":[{"arm":"Placebo","deltaMin":57,"sd":null},{"arm":"UMEC 125 µg","deltaMin":132,"sd":null},{"arm":"UMEC/VI 125/25 µg","deltaMin":120,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":39},"locations":{"siteCount":54,"countries":["United States","Chile","Romania","Russia","Slovakia","South Africa"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":109},"commonTop":["Headache","Nasopharyngitis","Ventricular extrasystoles","Extrasystoles","Back pain"]}}